Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Terpos, Evangelos; Katodritou, Eirini; de la Rubia, Javier; Hungria, Vania; Hulin, Cyrille; Roussou, Maria; Delforge, Michel; Bries, Greet; Stoppa, Anne-Marie; Aagesen, Jesper; Sargin, Deniz; Belch, Andrew; Ahlberg, Lucia; Diels, Joris; Olie, Robert; Robinson, Don; Spencer, Mike; Potamianou, Anna; van de Velde, Helgi; Dimopoulos, Meletios

doi:10.1111/ejh.13147

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Copy For Citation

Terpos E., Katodritou E., de la Rubia J., Hungria V., Hulin C., Roussou M., ...More

EUROPEAN JOURNAL OF HAEMATOLOGY, vol.101, no.4, pp.556-565, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 101 Issue: 4
Publication Date: 2018
Doi Number: 10.1111/ejh.13147
Journal Name: EUROPEAN JOURNAL OF HAEMATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.556-565
Istanbul University Affiliated: Yes

Abstract

Objective: The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE (R) OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice.